Antisera to Detect Phosphorylated Phosphoinositide-Dependent Kinase 1 (PDK-1)
Posted Nov 30 2006 4:00pm
Description of Invention: PDK-1 phosphorylates and activates a number of cellular kinases, and plays a major role in insulin and growth factor signaling. PDK-1 also represents a promising drug target for a number of cancers. Autophosphorylation at Ser244 (mouse) or Ser241 (human) is critical for PDK-1 activity.
Available for licensing are polyclonal rabbit antisera that specifically detect mouse PDK-1 protein phosphorylated at Ser244. These antisera are also expected to be specific for the human PDK-1 protein phosphorylated at Ser241.
Tool for screening PDK-1 autophosphorylation inhibitors for cancer and other indications
Tool for studying insulin and growth factor signaling
Inventors: Michael J Quon (NCCAM)
Patent Status: HHS, Reference No. E-330-2003/0
MJ Wick, FJ Ramos, H Chen, MJ Quon, LQ Dong, F Liu. Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. J Biol Chem. 2003 Oct 31;278(44):42913-42919. [ PubMed abs ]
Licensing Status: This technology is available as a research tool under a Biological Materials License.
Collaborative Research Opportunity: The NIH, NCCAM, Diabetes Unit is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize phospho-specific PDK-1 antibody and insulin signaling. Please contact Michael J. Quon, Chief, Diabetes Unit, NCCAM, NIH at email@example.com for more information.
Portfolios: Cancer Cancer - Research Materials Internal Medicine Internal Medicine - Research Materials
For Additional Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4426 Fax: 301-402-0220